Apex Biotechnology (TPE:1733) COGS-to-Revenue : 0.76 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology COGS-to-Revenue?

Apex Biotechnology's Cost of Goods Sold for the three months ended in Mar. 2024 was NT$341 Mil. Its Revenue for the three months ended in Mar. 2024 was NT$451 Mil.

Apex Biotechnology's COGS to Revenue for the three months ended in Mar. 2024 was 0.76.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Apex Biotechnology's Gross Margin % for the three months ended in Mar. 2024 was 24.30%.

Apex Biotechnology COGS-to-Revenue Historical Data

The historical data trend for Apex Biotechnology's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology COGS-to-Revenue Chart

Apex Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.73

0.77

0.73

0.74

0.68

Apex Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.69	0.71	0.67	0.67	0.76

Apex Biotechnology COGS-to-Revenue Calculation

Apex Biotechnology's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1145.421	/	1676.537
	=	0.68

Apex Biotechnology's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	341.126	/	450.658
	=	0.76

Apex Biotechnology (TPE:1733) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Apex Biotechnology's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	341.126 / 450.658
	=	24.30 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Apex Biotechnology COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Apex Biotechnology (TPE:1733) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078

Website

https://www.apexbio.com

Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines